Want to see JP:4575 full AI Analyst Report?

CanBas Co., Ltd. (4575) Price & Analysis

0 Followers

4575 Stock Chart & Stats

¥787.00

-¥23.00(-2.48%)

At close: Jan 08 4:00 PM EST

¥787.00

-¥23.00(-2.48%)

Day’s Range― - ―

52-Week Range¥506.00 - ¥1,317.00

Previous CloseN/A

Volume347.00K

Average Volume (3M)219.01K

Market Cap

¥14.47B

Enterprise Value¥12.28K

Total Cash (Recent Filing)¥1.45B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.78

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-66.43

Shares Outstanding19,713,655

10 Day Avg. Volume198,690

30 Day Avg. Volume219,010

Financial Highlights & Ratios

PEG Ratio-1.02

Price to Book (P/B)7.12

Price to Sales (P/S)0.00

P/FCF Ratio-8.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetThe absence of reported debt reduces interest and solvency pressure and preserves financial flexibility while CanBas funds oncology R&D. However, this strength is partly offset by operating losses and continuing capital consumption.

Oncology R&D SpecializationA concentrated oncology focus can help CanBas build specialized scientific capabilities and prioritize resources within a large therapeutic market. The durable benefit depends on translating its research into clinically and commercially viable products.

External Development PartnershipsExternal collaboration can expand CanBas’s development and commercialization capabilities beyond its small internal workforce of 14 employees. Partnerships may reduce execution constraints, although their financial impact is not yet demonstrated in the provided data.

Bears Say

No Reported RevenueThe absence of reported revenue indicates that CanBas has not yet established a stable commercial product base. This leaves the company dependent on future development milestones, partnerships, or financing rather than recurring operating income.

Persistent Net LossesLarge recurring losses and deeply negative returns on equity show that current activities are not economically self-sustaining. Without successful commercialization or meaningful cost improvement, continued losses could weaken capital resources and increase funding dependence.

Sustained Cash BurnPersistent operating and free-cash-flow deficits mean CanBas cannot currently fund its operations internally. Continued R&D and clinical spending therefore require external financing, creating ongoing liquidity and potential dilution risk over the medium term.

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?

CanBas Co., Ltd. lowest stock price was ¥506.00 and its highest was ¥1317.00 in the past 12 months.

What is CanBas Co., Ltd.’s market cap?

CanBas Co., Ltd.’s market cap is ¥14.47B.

When is CanBas Co., Ltd.’s upcoming earnings report date?

CanBas Co., Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 52 days.

How were CanBas Co., Ltd.’s earnings last quarter?

CanBas Co., Ltd. released its earnings results on Aug 12, 2026. The company reported -¥22.07 earnings per share for the quarter.

Is CanBas Co., Ltd. overvalued?

According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CanBas Co., Ltd. pay dividends?

CanBas Co., Ltd. does not currently pay dividends.

What is CanBas Co., Ltd.’s EPS estimate?

CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CanBas Co., Ltd. have?

CanBas Co., Ltd. has 19,713,655 shares outstanding.

What happened to CanBas Co., Ltd.’s price movement after its last earnings report?

CanBas Co., Ltd. reported an EPS of -¥22.07 in its last earnings report. Following the earnings report the stock price went down -1.195%.

Which hedge fund is a major shareholder of CanBas Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4575

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CanBas Co., Ltd.

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.